Which has preferable valuation and earnings, ALT or VTVT?

vTv Therapeutics has higher revenue and earnings than Altimmune. vTv Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 14,147.69 -$88.09M -$0.93 N/A vTv Therapeutics $1.02M 136.47 -$26.97M -$0.93 N/A

Is VALN or VTVT more profitable?

vTv Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. vTv Therapeutics' return on equity of 3.96% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% vTv Therapeutics N/A 3.96% 2.86%

vTv Therapeutics (VTVT) Competitors

$35.33 +1.41 (+4.16%)

As of 04:00 PM Eastern

Compare

VTVT vs. PRME, CTMX, ALT, VALN, and PROK

Should you buy vTv Therapeutics stock or one of its competitors? MarketBeat compares vTv Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with vTv Therapeutics include Prime Medicine (PRME), CytomX Therapeutics (CTMX), Altimmune (ALT), Valneva (VALN), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry.

How does vTv Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

In the previous week, Prime Medicine had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for vTv Therapeutics. Prime Medicine's average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score.

Company	Overall Sentiment
Prime Medicine	Neutral
vTv Therapeutics	Neutral

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prime Medicine has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Prime Medicine presently has a consensus price target of $7.38, indicating a potential upside of 127.62%. vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 50.01%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Prime Medicine is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

vTv Therapeutics has lower revenue, but higher earnings than Prime Medicine. vTv Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	126.39	-$201.14M	-$1.23	N/A
vTv Therapeutics	$1.02M	136.47	-$26.97M	-$0.93	N/A

vTv Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. vTv Therapeutics' return on equity of 3.96% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
vTv Therapeutics	N/A	3.96%	2.86%

Summary

Prime Medicine beats vTv Therapeutics on 9 of the 16 factors compared between the two stocks.

How does vTv Therapeutics compare to CytomX Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

vTv Therapeutics presently has a consensus price target of $53.00, indicating a potential upside of 50.01%. CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 284.13%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

vTv Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	136.47	-$26.97M	-$0.93	N/A
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A

vTv Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. vTv Therapeutics' return on equity of 3.96% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.33 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
CytomX Therapeutics	Neutral

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CytomX Therapeutics beats vTv Therapeutics on 11 of the 17 factors compared between the two stocks.

How does vTv Therapeutics compare to Altimmune?

Altimmune (NASDAQ:ALT) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Altimmune has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. vTv Therapeutics' return on equity of 3.96% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
vTv Therapeutics	N/A	3.96%	2.86%

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Altimmune had 3 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Altimmune and 0 mentions for vTv Therapeutics. Altimmune's average media sentiment score of 0.36 beat vTv Therapeutics' score of 0.00 indicating that Altimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Altimmune	Neutral
vTv Therapeutics	Neutral

vTv Therapeutics has higher revenue and earnings than Altimmune. vTv Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,147.69	-$88.09M	-$0.93	N/A
vTv Therapeutics	$1.02M	136.47	-$26.97M	-$0.93	N/A

Altimmune presently has a consensus target price of $15.71, indicating a potential upside of 440.01%. vTv Therapeutics has a consensus target price of $53.00, indicating a potential upside of 50.01%. Given Altimmune's higher probable upside, equities research analysts plainly believe Altimmune is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

vTv Therapeutics beats Altimmune on 8 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Valneva currently has a consensus price target of $11.98, indicating a potential upside of 121.76%. vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 50.01%. Given Valneva's higher possible upside, equities analysts plainly believe Valneva is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Valneva has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. vTv Therapeutics' return on equity of 3.96% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
vTv Therapeutics	N/A	3.96%	2.86%

In the previous week, Valneva's average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score.

Company	Overall Sentiment
Valneva	Neutral
vTv Therapeutics	Neutral

vTv Therapeutics has lower revenue, but higher earnings than Valneva. vTv Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A
vTv Therapeutics	$1.02M	136.47	-$26.97M	-$0.93	N/A

11.4% of Valneva shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

vTv Therapeutics beats Valneva on 9 of the 14 factors compared between the two stocks.

How does vTv Therapeutics compare to ProKidney?

vTv Therapeutics (NASDAQ:VTVT) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

vTv Therapeutics has higher revenue and earnings than ProKidney. vTv Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	136.47	-$26.97M	-$0.93	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

vTv Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. vTv Therapeutics' return on equity of 3.96% beat ProKidney's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
ProKidney	-8,131.50%	N/A	-21.39%

In the previous week, ProKidney's average media sentiment score of 1.42 beat vTv Therapeutics' score of 0.00 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
ProKidney	Positive

vTv Therapeutics currently has a consensus target price of $53.00, indicating a potential upside of 50.01%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 311.11%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

ProKidney beats vTv Therapeutics on 9 of the 16 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export

Metric	vTv Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$133.61M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-37.99	19.75	24.92	23.98
Price / Sales	136.47	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.16	8.29	10.79	6.50
Net Income	-$26.97M	$23.85M	$3.56B	$336.88M
7 Day Performance	9.58%	5.21%	1.67%	-0.22%
1 Month Performance	2.70%	2.19%	0.43%	0.77%
1 Year Performance	126.40%	60.99%	32.84%	31.57%

vTv Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTVT vTv Therapeutics	1.8957 of 5 stars	$35.33 +4.2%	$53.00 +50.0%	+118.1%	$133.61M	$1.02M	N/A	9
PRME Prime Medicine	1.6261 of 5 stars	$2.87 -1.0%	$7.65 +166.6%	N/A	$523.79M	$4.63M	N/A	N/A	Analyst Forecast
CTMX CytomX Therapeutics	2.6708 of 5 stars	$2.93 -3.6%	$12.10 +313.0%	+31.0%	$517.37M	$76.20M	N/A	170	High Trading Volume
ALT Altimmune	2.0546 of 5 stars	$2.62 -0.8%	$16.67 +536.1%	-58.4%	$513.41M	$40K	N/A	50	Analyst Forecast Options Volume
VALN Valneva	1.5964 of 5 stars	$5.36 -0.6%	$11.98 +123.4%	-5.4%	$511.43M	$197.56M	N/A	700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

vTv Therapeutics (VTVT) Competitors

VTVT vs. PRME, CTMX, ALT, VALN, and PROK

How does vTv Therapeutics compare to Prime Medicine?

Summary

How does vTv Therapeutics compare to CytomX Therapeutics?

Summary

How does vTv Therapeutics compare to Altimmune?

Summary

How does vTv Therapeutics compare to Valneva?

Summary

How does vTv Therapeutics compare to ProKidney?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

vTv Therapeutics (VTVT) Competitors

VTVT vs. PRME, CTMX, ALT, VALN, and PROK

How does vTv Therapeutics compare to Prime Medicine?

Does the media favor PRME or VTVT?

Do institutionals and insiders believe in PRME or VTVT?

Which has more risk & volatility, PRME or VTVT?

Do analysts recommend PRME or VTVT?

Which has higher valuation and earnings, PRME or VTVT?

Is PRME or VTVT more profitable?

Summary

How does vTv Therapeutics compare to CytomX Therapeutics?

Do analysts prefer VTVT or CTMX?

Which has more volatility & risk, VTVT or CTMX?

Which has preferable earnings & valuation, VTVT or CTMX?

Is VTVT or CTMX more profitable?

Does the media refer more to VTVT or CTMX?

Do institutionals & insiders believe in VTVT or CTMX?

Summary

How does vTv Therapeutics compare to Altimmune?

Which has more volatility & risk, ALT or VTVT?

Is ALT or VTVT more profitable?

Do institutionals and insiders believe in ALT or VTVT?

Does the media favor ALT or VTVT?

Which has preferable valuation and earnings, ALT or VTVT?

Do analysts rate ALT or VTVT?

Summary

How does vTv Therapeutics compare to Valneva?

Do analysts recommend VALN or VTVT?

Which has more risk and volatility, VALN or VTVT?

Is VALN or VTVT more profitable?

Does the media prefer VALN or VTVT?

Which has higher valuation & earnings, VALN or VTVT?

Do insiders and institutionals believe in VALN or VTVT?

Summary

How does vTv Therapeutics compare to ProKidney?

Do insiders & institutionals believe in VTVT or PROK?

Which has better valuation & earnings, VTVT or PROK?

Which has more risk & volatility, VTVT or PROK?

Is VTVT or PROK more profitable?

Does the media favor VTVT or PROK?

Do analysts recommend VTVT or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools